Commentary

Almost two-thirds of the Miami Breast Cancer Conference attendees believe that in 2002, anastrozole will be utilized a great deal as adjuvant endocrine therapy for postmenopausal breast cancer patients. Of note, nearly 20% believe anastrozole has almost completely replaced tamoxifen in these patients.

This viewpoint was confirmed in physicians’ predictions for clinical practice three years from now, with nearly three-quarters stating that anastrozole will be the most commonly utilized adjuvant endocrine therapy. Interestingly, there is a lack of support of the other aromatase inhibitors as adjuvant therapy. This is likely to continue until compelling, randomized clinical trial data become available for these agents.

Return